LA JOLLA - heute mit kräftigem Rebound?

 

La Jolla Pharmaceutical Company to Present at SG Cowen Healthcare Conference

SAN DIEGO, Mar 13, 2003 /PRNewswire-FirstCall via COMTEX/ -- La Jolla Pharmaceutical Company (Nasdaq: LJPC) announced today that its Chairman and Chief Executive Officer, Steven B. Engle, will present at the SG Cowen Securities Corporation 23rd Annual Health Care Conference at The Boston Marriott Copley Place, Boston, MA. Mr. Engle will present on Wednesday, March 19, 2003 at 10:15 a.m. and again at 11:15 a.m. Eastern time. An audio webcast of the presentation will be available via the Company's web site at www.ljpc.com or at SG Cowen's web site at www.sgcowen.com .

La Jolla Pharmaceutical Company is a biotechnology company developing therapeutics for antibody-mediated autoimmune diseases afflicting several million people in the United States and Europe. The Company is developing Riquent(TM), formerly known as LJP 394, for the treatment of lupus kidney disease, a leading cause of sickness and death in patients with lupus. The Company is also developing LJP 1082 for the treatment of antibody-mediated thrombosis, a condition in which patients suffer from recurrent stroke, deep-vein thrombosis and other thrombotic events. The Company's common stock is traded on The Nasdaq Stock Market under the symbol LJPC. For more information about the Company, visit its Web site: http://www.ljpc.com .

 

Kann scih nur noch um Tage/Wochen oder Monate handeln!
Werde nächste Woche eine weitere Position kaufen.  

NEW YORK, March 13 (Reuters) - UBS Warburg (News - Websites) said on Thursday it cut its rating on La Jolla Pharmaceutical Co. (NasdaqNM:LJPC - News) to "neutral" from "buy" based upon its increasing belief that the company will need to conduct an additional Phase III trial for its lupus nephritis drug, Riquent.

Warburg thinks the Phase III trials will have to be repeated. The company doesn't have sufficient money to repeat the trial.

 

aber ich denke, dass Medikament wird keine weitere Testphase 3
durchlaufen müssen. Die Chancen stehen gut, um das Medikament
auch jetzt schon zuzulassen! Wir werden sehen!  

La Jolla Pharma bei 4 Dollar, macht satte 100% seit Februar...

Grüße
Pavian  

mal sehen ob ich meinen kauf kurs
von 3.15 irgentwann noch erlebe :)

mfg ht  

langsam wieder einsammeln?
Was denkt ihr? Das Chancen/Risiko Verhältnis wäre eigentlich einen Kauf wert!

Glaub werd mir ein paar ins Depot legen!

xpfuture  

ausgebildet. Wenn´s am Montag in den USA nach oben geht spricht sehr viel für eine Trendumkehr.

Charttechnisch sollten wir das Tief eigentlich geseh´n haben. Die Marke um USD 1,40 sollten wir nicht mehr unterbieten. Auch Fast- u. Low Stochastic im überverkauften Bereich!!!!
Bei Ausbruch aus dem Abwärtstrend seit dem Hoch Anfang Dezember sollte es ziemlich schnell nach oben geh´n.

Fundamental ist´s aber etwas riskant - erste Entscheidungen der FDA sollten noch dieses Monat fallen - falls diese wieder negativ zur Zulassung zum Medikament Riquent ausfällt, geht´s sicher unter 1 USD. Bei Zulassung gibt´s kein halten für den Kurs.
Positiv sehe ich den Insiderkauf von 77k Shares von Gonzales Alejandro.

Alles in allem ein gutes Chance/Risiko Verhältnis

xpfuture  

 

La Jolla Pharmaceutical Announces Outcome of Recent FDA Discussions
Monday March 14, 7:30 am ET

SAN DIEGO, March 14 /PRNewswire-FirstCall/ -- La Jolla Pharmaceutical Company (Nasdaq: LJPC - News) today announced that, based on the outcome of a meeting with the United States Food and Drug Administration (FDA) on March 11, 2005, its treatment for lupus renal disease, Riquent® (abetimus sodium), is unlikely to receive an accelerated approval under the FDA's Subpart H regulation. The Company plans to continue the ongoing clinical benefit trial and expects to continue discussions with the FDA about ways to enhance the trial, including, as previously announced, the addition of a higher dose to the study.
ADVERTISEMENT


This decision follows a number of meetings with the FDA since October 2004, when the Company received an Approvable Letter from the FDA for Riquent. The Approvable Letter indicated that an additional trial demonstrating clinical benefit would be required prior to approval of Riquent and that the Company's ongoing trial, initiated in August 2004, would appear to satisfy this requirement.

"We are disappointed that the FDA determined that accelerated approval is not applicable to the approval of Riquent," stated Steve Engle, Chairman and CEO of La Jolla Pharmaceutical Company. "We recognize the urgent need for safer and more effective treatments for lupus patients, as no new drugs have been approved for this disease in the United States in almost 40 years."

xpfuture  

0,78 US-Cent. Das sind ja schon fast Einstiegskurse. Oder was meint ihr?  

Schwer zu sagen Happy Berti. Eventuell morgen ein kleines Reversal.
Denke aber das es hier in den nächsten Tagen weiter runter geh´n wird.
Das Geld geht zu Ende und ein positiver Erfolg auf Zulassung rückt in immer weitere Entfernung. Ein Zock wird allerdings immer mal drin sein.

xpfuture  

LaJolla Pharma gets FDA fast track status for Riquent

LaJolla Pharmaceutical Co. said the Food and Drug Administration has granted 'fast track' status for its Riquent treatment of lupus renal disease. The company said it currently only has limited financial resources and if it does not receive funding from a collaborative agreement or obtain other financing in the near future, it will not have sufficient resources to complete the ongoing clinical benefit trial or to continue its operations beginning in the first quarter of 2006.

 

heute wieder kräftig bergauf!

xpfuture  

eine Woche Wartezeit für 10% ist ok. Brauche das Geld für kleinen Pennystock!  

@pomerol, das war wohl zu früh

Topper J. (Mananger bei LJPC) hat sich 20 Mio. Stk. ins Depot gelegt:

http://www.sec.gov/Archives/edgar/data/920465/.../xslF345X02/doc4.xml

xpfuture  

Was ist denn da eigentlech los? weiss da irgendjemand etwas mehr?